[HTML][HTML] Hallmarks of neurodegenerative diseases
DM Wilson, MR Cookson, L Van Den Bosch… - Cell, 2023 - cell.com
Decades of research have identified genetic factors and biochemical pathways involved in
neurodegenerative diseases (NDDs). We present evidence for the following eight hallmarks …
neurodegenerative diseases (NDDs). We present evidence for the following eight hallmarks …
Blood biomarkers for Alzheimer's disease in clinical practice and trials
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape
Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology
Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …
Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers
Importance Alzheimer disease (AD) pathology starts with a prolonged phase of β-amyloid
(Aβ) accumulation without symptoms. The duration of this phase differs greatly among …
(Aβ) accumulation without symptoms. The duration of this phase differs greatly among …
[HTML][HTML] A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …
[HTML][HTML] Aducanumab: appropriate use recommendations update
Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with
mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Aducanumab …
mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Aducanumab …
[HTML][HTML] Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
The role of amyloid PET in imaging neurodegenerative disorders: a review
M Chapleau, L Iaccarino… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Imaging of amyloid deposition using PET has been available in research studies for 2
decades and has been approved for clinical use by the US Food and Drug Administration …
decades and has been approved for clinical use by the US Food and Drug Administration …
[HTML][HTML] The use of neuroimaging techniques in the early and differential diagnosis of dementia
L Chouliaras, JT O'Brien - Molecular Psychiatry, 2023 - nature.com
Dementia is a leading cause of disability and death worldwide. At present there is no
disease modifying treatment for any of the most common types of dementia such as …
disease modifying treatment for any of the most common types of dementia such as …